Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: gracia gil j. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Among authors: gracia gil j. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, Berenguer-Ruiz L, Candeliere Merlicco A, Martinez-Navarro ML, Gracia Gil J, Romero-Sanchez CM, Alfaro-Saez A, Diaz I, Gimenez-Martinez J, Mendez-Miralles MA, Millan-Pascual J, Jimenez-Pancho J, Mola S, Sempere AP. Fernandez-Diaz E, et al. Among authors: gracia gil j. Ann Clin Transl Neurol. 2021 Feb;8(2):385-394. doi: 10.1002/acn3.51282. Epub 2020 Dec 25. Ann Clin Transl Neurol. 2021. PMID: 33369288 Free PMC article.
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Fernández-Díaz E, Gracia-Gil J, García-García JG, Palao M, Romero-Sánchez CM, Segura T. Fernández-Díaz E, et al. Among authors: gracia gil j. Mult Scler Relat Disord. 2020 Oct;45:102402. doi: 10.1016/j.msard.2020.102402. Epub 2020 Jul 17. Mult Scler Relat Disord. 2020. PMID: 32711297 Free PMC article.
Multiple sclerosis following SARS-CoV-2 infection.
Palao M, Fernández-Díaz E, Gracia-Gil J, Romero-Sánchez CM, Díaz-Maroto I, Segura T. Palao M, et al. Among authors: gracia gil j. Mult Scler Relat Disord. 2020 Oct;45:102377. doi: 10.1016/j.msard.2020.102377. Epub 2020 Jul 7. Mult Scler Relat Disord. 2020. PMID: 32698095 Free PMC article.
Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry.
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, González E, Redondo-Peñas I, Perona-Moratalla AB, Del Valle-Pérez JA, Gracia-Gil J, Rojas-Bartolomé L, Feria-Vilar I, Monteagudo M, Palao M, Palazón-García E, Alcahut-Rodríguez C, Sopelana-Garay D, Moreno Y, Ahmad J, Segura T. Romero-Sánchez CM, et al. Among authors: gracia gil j. Neurology. 2020 Aug 25;95(8):e1060-e1070. doi: 10.1212/WNL.0000000000009937. Epub 2020 Jun 1. Neurology. 2020. PMID: 32482845 Free PMC article.
Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.
Villaverde-González R, Gracia Gil J, Pérez Sempere A, Millán Pascual J, Marín Marín J, Carcelén Gadea M, Gabaldón Torres L, Moreno Escribano A, Candeliere Merlicco A. Villaverde-González R, et al. Among authors: gracia gil j. Eur Neurol. 2017;77(3-4):130-136. doi: 10.1159/000453333. Epub 2017 Jan 5. Eur Neurol. 2017. PMID: 28052269
Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ© (Multiple Sclerosis Treatment Concerns Questionnaire).
Muntéis Olivas E, Navarro Mascarell G, Meca Lallana J, Maestre Martínez A, Pérez Sempere Á, Gracia Gil J, Pato Pato A. Muntéis Olivas E, et al. Among authors: gracia gil j. Neurologia. 2017 Jan-Feb;32(1):29-39. doi: 10.1016/j.nrl.2014.12.011. Epub 2015 Feb 16. Neurologia. 2017. PMID: 25697827 Free article. English, Spanish.
11 results